Table of Content

Introduction
Executive Summary
Human Immunodeficiency Virus Type 1 (HIV-1) Infection: Overview
? Causes
? Mechanism of Action
? Signs and Symptoms
? Diagnosis
? Disease Management
Pipeline Therapeutics
? Comparative Analysis
Therapeutic Assessment
? Assessment by Product Type
? Assessment by Stage and Product Type
? Assessment by Route of Administration
? Assessment by Stage and Route of Administration
? Assessment by Molecule Type
? Assessment by Stage and Molecule Type
Human Immunodeficiency Virus Type 1 (HIV-1) Infection – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
? Human Immunodeficiency Virus Type 1 (HIV-1) Infection companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Human Immunodeficiency Virus Type 1 (HIV-1) Infection Collaboration Deals
? Company-Company Collaborations (Licensing / Partnering) Analysis
? Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
? Comparative Analysis
UB421: United BioPharma
? Product Description
? Research and Development
? Product Development Activities
Drug profiles in the detailed report?..
Mid Stage Products (Phase II)
? Comparative Analysis
PRO140: CytoDyn Inc.
? Product Description
? Research and Development
? Product Development Activities
Drug profiles in the detailed report?..
Early Stage Products (Phase I)
? Comparative Analysis
Drug Name: Company Name
? Product Description
? Research and Development
? Product Development Activities
Drug profiles in the detailed report?..
Inactive Products
? Comparative Analysis
Human Immunodeficiency Virus Type 1 (HIV-1) Infection Key Companies
Human Immunodeficiency Virus Type 1 (HIV-1) Infection Key Products
Human Immunodeficiency Virus Type 1 (HIV-1) Infection- Unmet Needs
Human Immunodeficiency Virus Type 1 (HIV-1) Infection- Market Drivers and Barriers
Human Immunodeficiency Virus Type 1 (HIV-1) Infection- Future Perspectives and Conclusion
Human Immunodeficiency Virus Type 1 (HIV-1) Infection Analyst Views
Human Immunodeficiency Virus Type 1 (HIV-1) Infection Key Companies
Appendix



List of Figures


Figure 1 Total Products for Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products


List of Tables


Table 1 Total Products for Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products